AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

Rhea-AI Summary

AEON Biopharma (NYSE American: AEON) is presenting new analytical and functional data on ABP-450 at the 68th American Headache Society meeting on June 4, 2026. The poster shows structural and functional comparability of ABP-450 to BOTOX using genomic alignment, LC-MS peptide mapping, and LD50 potency assays.

AI-generated analysis. Not financial advice.

News Market Reaction – AEON

+0.79%

1 alert

+0.79% News Effect

On the day this news was published, AEON gained 0.79%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Sequence coverage: 93%–99% AHS meeting number: 68th Meeting dates: June 4–7, 2026 +2 more

5 metrics

Sequence coverage 93%–99% LC-MS peptide mapping across BoNT/A1 and accessory proteins

AHS meeting number 68th 68th Annual Scientific Meeting of the American Headache Society

Meeting dates June 4–7, 2026 AHS Annual Scientific Meeting in Orlando, Florida

Abstract number 2349958 Poster presentation abstract number in main window

Presentation time window 2:00 pm – 5:00 pm ET Poster session on Thursday June 4, 2026

Market Reality Check

Price: $0.7368 Vol: Volume 8,569 is well belo...

low vol

$0.7368 Last Close

Volume Volume 8,569 is well below the 20-day average 62,366, indicating limited pre-news positioning. low

Technical Shares at 0.7378 are trading below the 200-day MA of 0.95 and are 49.12% under the 52-week high.

Peers on Argus

AEON was down 2.49% pre-news with light volume, while peers showed mixed moves: ...

1 Down

AEON was down 2.49% pre-news with light volume, while peers showed mixed moves: several names (APRE, CSCI, DWTX, PCSA) were down but RNAZ was up 18.59%. Only RNAZ appeared in the momentum scanner, moving down there, so recent trading did not reflect a coordinated sector rotation.

Historical Context

5 past events · Latest: May 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 14	Q1 results & update	Positive	-9.9%	Q1 2026 results, FDA biosimilar feedback, $6M PIPE and major debt cut.
Apr 24	Shareholder meeting notice	Negative	-0.9%	Annual meeting details and audit going concern qualification with limited cash runway.
Apr 03	CFO inducement grants	Positive	+2.4%	Appointment of new CFO and RSU/PSU inducement equity awards tied to compliance.
Apr 03	Listing noncompliance notice	Negative	+2.4%	NYSE American notice citing ~$55M stockholders’ deficit and continued listing risk.
Mar 30	FY 2025 earnings	Positive	-0.5%	Full-year 2025 results with 100% sequence match data and constructive FDA biosimilar feedback.

Pattern Detected

Recent news often shows mixed alignment: positive balance sheet and biosimilar updates have sometimes been followed by negative price reactions, while listing-risk headlines have seen occasional upside moves.

Recent Company History

Over the last few months, AEON has focused on its ABP-450 biosimilar program and balance sheet repair. Earnings updates on Mar 30 and May 14 highlighted analytical similarity to BOTOX®, FDA BPD feedback, and debt reduction via a $6M PIPE and note exchanges, yet shares slipped after both. NYSE American noncompliance notices on Mar 30/Apr 3 coincided with modest gains. Today’s analytical/functional comparability data at AHS extends the same biosimilar narrative.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-09

An effective S-3 shelf filed on 2026-02-09 registers the resale of up to 51,292,953 Class A shares held or issuable to existing investors. AEON receives no proceeds from resales but may receive cash upon warrant exercises. The prospectus reiterates auditor language about substantial doubt regarding AEON’s ability to continue as a going concern.

Market Pulse Summary

This announcement adds functional comparability results to AEON’s existing analytical data for ABP‑4...

Analysis

This announcement adds functional comparability results to AEON’s existing analytical data for ABP‑450, showing 93–99% sequence coverage and LD50 potency equivalence versus BOTOX®. It fits the company’s “analytical‑first” biosimilar strategy described in recent SEC filings. At the same time, those filings note substantial doubt about AEON’s ability to continue as a going concern and a significant registered resale overhang, underscoring financing and dilution risks alongside scientific progress.

Key Terms

biosimilar, onabotulinumtoxinA, genomic sequence alignment, lc-ms peptide mapping, +3 more

7 terms

biosimilar medical

"advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use"

A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.

onabotulinumtoxinA medical

"ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use"

Onabotulinumtoxina is a prescription form of botulinum toxin type A, a purified protein given by injection in very small doses to temporarily relax muscles and block certain nerve signals; it is used for cosmetic purposes like reducing wrinkles and for medical conditions such as chronic migraine, muscle spasms, and excessive sweating. Investors track its sales, regulatory approvals, patent life, and safety profile because changes to demand, labeling, or competition for this single product can significantly affect a drugmaker’s revenue and growth—similar to how a popular flagship product can drive an electronics company’s fortunes.

genomic sequence alignment medical

"biological activity between ABP-450 and BOTOX® across multiple orthogonal analytical approaches: genomic sequence alignment"

Comparing two or more DNA or RNA strings to find where they match, differ, or have been rearranged — like lining up different versions of a recipe to spot added, removed, or changed ingredients. Investors should care because accurate sequence alignment underpins genetic tests, drug target discovery, and biotech product validation; errors or advances in alignment methods can speed development, change costs, affect regulatory confidence and alter a company’s commercial prospects.

lc-ms peptide mapping medical

"biological activity between ABP-450 and BOTOX® across multiple orthogonal analytical approaches: genomic sequence alignment, LC-MS peptide mapping"

A laboratory technique that breaks a protein into smaller pieces, separates those pieces by liquid flow, and measures their exact masses to confirm the protein’s identity and detect changes or impurities. Think of it like cutting a long string of colored beads, lining the beads up, and checking each bead’s color and size to ensure the original pattern is correct. Investors care because it’s a key test used to verify drug or biologic quality, manufacturing consistency and regulatory compliance, all of which affect product value and risk.

ld50 potency assay medical

"genomic sequence alignment, LC-MS peptide mapping, and the LD50 potency assay"

An LD50 potency assay measures how much of a drug, chemical or biological agent is needed to cause a harmful effect in half of a test population, giving a single number that captures its strength and risk. For investors, this result is a simple indicator of safety and dosing risk—like knowing how spicy a sauce is before selling it—because it affects regulatory approval, labeling, potential liability and the size of the usable market for a product.

neurotoxin medical

"sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins"

A neurotoxin is a chemical or biological substance that harms the nervous system, interfering with how nerves send signals — like a short circuit or traffic jam in the body's wiring. For investors, neurotoxins matter because they can trigger strict safety rules, expensive testing and development, liability exposure, or shifts in market demand for products and treatments, all of which can affect a company’s costs, approvals and future revenues.

botulinum toxin medical

"The AHS Annual Scientific Meeting is a leading forum for headache specialists ... for botulinum toxin."

A potent bacterial protein that temporarily blocks nerve signals to muscles, causing controlled muscle relaxation; it is used as a prescription treatment for movement disorders, excessive sweating and other medical conditions, and widely in cosmetic procedures to reduce wrinkles. For investors, botulinum toxin is a high-value pharmaceutical product whose sales depend on regulatory approval, safety profile, manufacturing precision and market demand—think of it as a precision tool whose performance and rules determine its commercial value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.  

The data being presented today builds on previously reported primary structure findings by adding functional evidence demonstrating highly similar biological activity between ABP-450 and BOTOX® across multiple orthogonal analytical approaches: genomic sequence alignment, LC-MS peptide mapping, and the LD₅₀ potency assay. LC-MS peptide mapping demonstrated 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins (NTNH, HA70, HA33, and HA17), with no variant peptides observed between ABP-450 and BOTOX®.  In the LD₅₀ potency assay, all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference results, reinforcing functional similarity and further strengthening the analytical foundation supporting biosimilarity.

The AHS Annual Scientific Meeting is a leading forum for headache specialists and a central venue for advancing clinical and scientific dialogue in chronic migraine, the largest therapeutic indication for botulinum toxin. BOTOX® is currently the only botulinum toxin therapy approved for the treatment of chronic migraine.

AHS 2026 Presentation Details (Today)

Title: Establishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity

Format: Poster presentation (abstract #: 2349958, main window)

Presenter: Chad K. Oh, M.D., Chief Medical Officer, AEON Biopharma

Date: Thursday June 4, 2026

Time: 2:00 pm – 5:00 pm ET

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include specific statements regarding the potential for ABP-450 to demonstrate biosimilarity to BOTOX® based on analytical and functional data, the implications of such data for the development and regulatory pathway of ABP-450, and AEON’s plans to pursue full-label U.S. market entry for therapeutic indications. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this press release contains time-sensitive information that reflects management’s best analysis only as of the date of this press release. The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in the Company’s periodic filings with the SEC or Canadian securities regulators.

Contacts

Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com

Source: AEON Biopharma

FAQ

What data is AEON Biopharma (AEON) presenting on ABP-450 at AHS 2026?

AEON is presenting analytical and functional data supporting structural and functional comparability of ABP-450 to BOTOX. According to AEON, results include genomic sequence alignment, LC-MS peptide mapping, and LD50 potency assays, all aimed at supporting ABP-450’s biosimilarity for therapeutic use.

How does ABP-450 compare structurally to BOTOX in AEON Biopharma’s June 2026 AHS poster?

AEON reports that LC-MS peptide mapping showed 93%-99% sequence coverage for ABP-450 and BOTOX core and accessory proteins. According to AEON, no variant peptides were observed between ABP-450 and BOTOX, supporting structural comparability across the neurotoxin and associated complexing proteins.

What did the LD50 potency assay show about ABP-450 versus BOTOX according to AEON (AEON)?

The LD50 potency assay showed all ABP-450 lots within predefined equivalence criteria based on BOTOX reference results. According to AEON, this reinforces functional similarity between ABP-450 and BOTOX and further strengthens the analytical foundation for ABP-450’s proposed biosimilarity.

When and where is AEON Biopharma’s ABP-450 poster presented at the American Headache Society 2026 meeting?

AEON’s ABP-450 poster is presented June 4, 2026, from 2:00 pm to 5:00 pm ET. According to AEON, it appears in the main window poster session at the 68th Annual Scientific Meeting of the American Headache Society in Orlando, Florida.

What is ABP-450 and what indication is AEON targeting compared with BOTOX?

ABP-450 is a botulinum toxin product AEON is advancing as a biosimilar to BOTOX for therapeutic use. According to AEON, the AHS meeting focuses on chronic migraine, currently the largest botulinum toxin indication, where BOTOX is the only approved botulinum toxin therapy.